![]() ![]() We considered the following PTs as related to AKI: ‘acute kidney injury ’, ‘subacute kidney injury ’, ‘blood creatinine increased ’, ‘blood urea abnormal ’, ‘glomerular filtration rate decreased ’, ‘renal impairment ’, ‘oliguria ’, ‘anuria ’, ‘dialysis ’, ‘proteinuria ’, ‘renal tubular injury ’, ‘nephropathy toxic ’, ‘nephritis allergic ’, and ‘tubulointerstitial nephritis ’. We described all reports to VAERS submitted for persons vaccinated with COVID-19 Vaccines during the period December 2020 through June 2021.ĪKI was based on Medical Dictionary for Regulatory Activities (MedDRA, version 24.0) at the preferred term (PT) level. We defined the onset of AEs by calculating the interval between vaccination date and symptom onset date. AE information includes vaccination date, symptom onset date, AE description, and prognosis. Vaccine information includes vaccine manufacturers. Patient information includes demographic data, coexisting current illnesses, and comorbidities. VAERS data contains the following files: VAERSDATA.CSV (including reports and patient information), VAERSVAX.CSV (including vaccine information), and VAERSSYMPTOMS.CSV (including the AE information). VAERS acts as an early warning system to test for possible safety issues with US-licensed vaccines by collecting information about AEs after vaccination. VAERS is a self-reporting system for post-vaccination AEs jointly administered by the Centers for Disease Control and Prevention and the FDA. ![]() This study aimed to investigate the demographics, clinical features, and outcomes of AKI after COVID-19 vaccines across different vaccine manufacturers in the real world, relying on reports from the Vaccine Adverse Event Reporting System (VAERS). Therefore, post-marketing surveillance is needed for such increasing concerns. Individuals with old age, preexisting CKD, or other comorbidities are at risk for COVID-19 infection, and they are also more likely to develop AKI after vaccination. ![]() Moreover, a proportion of the reported patients progressed to end-stage kidney disease (ESKD), requiring renal replacement therapy.ĪKI is associated with poor outcomes due to the development of chronic kidney disease (CKD) and ESKD and a higher mortality rate. ![]() Interestingly, acute kidney injury (AKI) is accompanied in most such conditions, as exemplified by the finding that AKI was observed in most published cases of MCD and over 70% of glomerulonephritis. In the meantime, reports of rare adverse events (AEs) are emerging in the short interval of vaccine injection, in terms of de novo or recurrent kidney diseases, such as minimal change disease (MCD), anti-neutrophil cytoplasmic antibody-associated glomerulonephritis, IgA nephropathy, membranous nephropathy, anti-glomerular basement membrane nephritis, acute tubulointerstitial nephritis, thrombotic thrombocytopenic Purpura, and thrombotic microangiopathy. As of December 2021, more than 493 million doses have been administrated in the United States. Aside from nonsevere transient local and systemic reactions, those vaccines have been proven safe and effective by large clinical trials. The US Food and Drug Administration (FDA) authorized two messenger RNA-based vaccines (Pfizer-BioNTech and Moderna) in December 2020 and an adenovirus vector-based vaccine (Janssen) in February 2021 for emergency use. The vaccination campaign is urgently ongoing worldwide to contain the pandemic by reducing morbidity and mortality. Globally, as of 17 December 2021, more than 271 million confirmed cases of coronavirus disease 2019 (COVID-19) and over 5 million COVID-19-related deaths had been reported by the world health organization (WHO). ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |